Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages e498-e509

  Sharabi, Andrew B ^a,b   Lim, Michael ^b,c   DeWeese, Theodore L ^b,c   Drake, Charles G ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CALRETICULIN; CD31 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR6; CISPLATIN; CXCL16 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; GLYCINE; HIGH MOBILITY GROUP B1 PROTEIN; HLA G ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; TEMOZOLOMIDE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASOACTIVE INTESTINAL POLYPEPTIDE; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; FEMALE GENITAL TRACT CANCER; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; LUNG CANCER; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; RADIOSENSITIZING IMMUNOTHERAPY; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT INDICATION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; CD8+ T LYMPHOCYTE; CELL DEATH; CHEMORADIOTHERAPY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RADIOGRAPHY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CHEMORADIOTHERAPY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84953874197     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00007-8     Document Type: Review

References (88)

1. Gunderson LL, Tepper JE Clinical radiation oncology 2012, Elsevier, Philadelphia, PA.
2. Order SE The effects of therapeutic irradiation on lymphocytes and immunity. Cancer 1977, 39(suppl 2):737-743.
3. Dyk JV The modern technology of radiation oncology 2013, Medical Physics Publishing, Madison, WI.
4. Jaffray D, Kupelian P, Djemil T, Macklis RM Review of image-guided radiation therapy. Expert Rev Anticancer Ther 2007, 7:89-103.
5. Stone HB, Peters LJ, Milas L Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979, 63:1229-1235.
6. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
7. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
8. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013, 182:2345-2354.
9. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11(2 Pt 1):728-734.
10. Friedman EJ Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002, 8:1765-1780.
11. Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis. Strahlenther Onkol 2004, 180:187-193. (in German).
12. Couzin-Frankel J Breakthrough of the year 2013.Cancer immunotherapy. Science 2013, 342:1432-1433.
13. Pardoll D, Drake C Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012, 209:201-209.
14. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
15. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712.
16. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
17. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
18. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
19. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
20. Drake CG, McDermott DF, Sznol M, et al. Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. Proc Am Soc Clin Oncol 2013, 31(suppl):4514. (abstr).
21. Mole RH Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26:234-241.
22. Neefjes J, Jongsma ML, Paul P, Bakke O Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011, 11:823-836.
23. Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015, 3:345-355.
24. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271.
25. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
26. Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 2012, 7:e32542.
27. Hauser SH, Calorini L, Wazer DE, Gattoni-Celli S Radiation-enhanced expression of major histocompatibility complex class I antigen H-2Db in B16 melanoma cells. Cancer Res 1993, 53:1952-1955.
28. Verbrugge I, Gasparini A, Haynes NM, et al. The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. Radiat Res 2014, 182:219-229.
29. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014, 5:403-416.
30. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002, 72:1084-1091.
31. Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5:825-830.
32. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61.
33. Kim JY, Son YO, Park SW, et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006, 38:474-484.
34. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011, 2011:439752.
35. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170:6338-6347.
36. Kuwabara M, Takahashi K, Inanami O Induction of apoptosis through the activation of SAPK/JNK followed by the expression of death receptor Fas in X-irradiated cells. J Radiat Res 2003, 44:203-209.
37. Kolesnick R, Fuks Z Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
38. Steinman RM Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012, 30:1-22.
39. Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012, 189:558-566.
40. Parker JJ, Jones JC, Strober S, Knox SJ Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol 2013, 148:44-55.
41. Merrick A, Errington F, Milward K, et al. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer 2005, 92:1450-1458.
42. Janeway CA, Goodnow CC, Medzhitov R Danger-pathogen on the premises! Immunological tolerance. Curr Biol 1996, 6:519-522.
43. Kono H, Rock KL How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-289.
44. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
45. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74:5458-5468.
46. Ishihara H, Tsuneoka K, Dimchev AB, Shikita M Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 1993, 133:321-326.
47. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 1989, 86:10104-10107.
48. Hong JH, Chiang CS, Tsao CY, Lin PY, McBride WH, Wu CJ Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999, 75:1421-1427.
49. Drake CG Radiation-induced immune modulation 2011, Springer, New York, NY.
50. Bouquet F, Pal A, Pilones KA, et al. TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 2011, 17:6754-6765.
51. Young KH, Newell P, Cottam B, et al. TGFbeta inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunol Res 2014, 2:1011-1022.
52. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003, 4:1009-1015.
53. Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008, 68:1319-1329.
54. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124:687-695.
55. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013, 86:343-349.
56. Schaue D, Ratikan JA, Iwamoto KS, McBride WH Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012, 83:1306-1310.
57. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
58. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
59. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
60. Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003, 63:1990-1993.
61. Cao ZA, Daniel D, Hanahan D Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002, 2:11.
62. Battaglia A, Buzzonetti A, Martinelli E, et al. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010, 76:1546-1553.
63. Dunn GP, Old LJ, Schreiber RD The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
64. Forrester JV, Xu H, Lambe T, Cornall R Immune privilege or privileged immunity?. Mucosal Immunol 2008, 1:372-381.
65. Ke Y, Sun D, Jiang G, Kaplan HJ, Shao H PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells. J Leukoc Biol 2010, 88:1241-1249.
66. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002, 62:1462-1470.
67. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008, 181:3099-3107.
68. Hallahan D, Kuchibhotla J, Wyble C Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996, 56:5150-5155.
69. Ariyoshi K, Takabatake T, Shinagawa M, et al. Age dependence of hematopoietic progenitor survival and chemokine family gene induction after gamma irradiation in bone marrow tissue in C3H/He mice. Radiat Res 2014, 181:302-313.
70. Quarmby S, Hunter RD, Kumar S Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 2000, 20:3375-3381.
71. Matsumura S, Demaria S Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 2010, 173:418-425.
72. Parikh F, Duluc D, Imai N, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 2014, 74:7205-7216.
73. Bernstein MB, Garnett CT, Zhang H, et al. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 2014, 29:153-161.
74. Kachikwu EL, Iwamoto KS, Liao YP, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 2011, 81:1128-1135.
75. Wirsdorfer F, Cappuccini F, Niazman M, et al. Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells. Radiat Oncol 2014, 9:98.
76. Sakaguchi S, Yamaguchi T, Nomura T, Ono M Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
77. Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009, 69:4309-4318.
78. Le DT, Jaffee EM Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012, 72:3439-3444.
79. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013, 110:17945-17950.
80. Yoshimoto Y, Suzuki Y, Mimura K, et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One 2014, 9:e92572.
81. Belcaid Z, Phallen JA, Zeng J, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014, 9:e101764.
82. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
83. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
84. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
85. Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015, 3:610-619.
86. Demaria S, Formenti SC Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012, 2:153.
87. Teply BA, Lipson EJ Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 2014, 28(suppl 3):30-38.
88. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015, 92:368-375.